This product is a Chimeric (mouse/human) IgG4, κ antibody that can recognize human SDC1.
Figure 1 Internalization of nBT062 and Indatuximab Ravtansine.
Time dependent distribution of fluorescently labelled indatuximab ravtansine in SK-BR-3 cells. Quantification of (a) total number of indatuximab ravtansine-DyLight488 clusters, (b) total number of extracellular indatuximab ravtansine-DyLight488 clusters, (c) total number of intracellular indatuximab ravtansine-DyLight488 clusters, and (d) percentage of intracellular indatuximab ravtansine-DyLight488 clusters in relation to total cluster number. Error bars, SEM; n = 3 for all groups.
Schönfeld, K., Herbener, P., Zuber, C., Häder, T., Bernöster, K., Uherek, C., & Schüttrumpf, J. (2018). Activity of indatuximab ravtansine against triple-negative breast cancer in preclinical tumor models. Pharmaceutical research, 35(6), 118.
Figure 2 Internalization of indatuximab ravtansine through the endosomal (I) and lysosomal (II) pathway in SK-BR-3 cells.
Grouped panels represent analyses at 1 and 4 h after initial antibody binding. (a) Merged DyLight488 (green, indatuximab ravtansine) and Cy3 (red, EEA1 [I]; LAMP1 [II]) fluorescent z-stack recordings. (b) Cy3 (EEA1 [I]; LAMP1 [II]) fluorescent z-stack recordings. (c) DyLight488 (indatuximab ravtansine) fluorescent z-stack recordings. (d) 3-dimensional reconstruction of cell nucleus (light grey, nucleus) and portions of DyLight488 fluorescence co-localized to EEA1-postive endosomes [I]; LAMP1-postive lysosomes [II] (yellow, Coloc).
Schönfeld, K., Herbener, P., Zuber, C., Häder, T., Bernöster, K., Uherek, C., & Schüttrumpf, J. (2018). Activity of indatuximab ravtansine against triple-negative breast cancer in preclinical tumor models. Pharmaceutical research, 35(6), 118.
Figure 3 Representative staining of CD138.
IHC CD138 staining in (a) MAXF1384 xenograft model with low CD138 expression treated with placebo (PBS), 2 mg/kg indatuximab ravtansine or 10 mg/kg docetaxel and (b) MAXF401 xenograft model with high CD138 expression treated with placebo (PBS) or 1 mg/kg indatuximab ravtansine, using monoclonal mouse anti-CD138 antibody and H&E.
Schönfeld, K., Herbener, P., Zuber, C., Häder, T., Bernöster, K., Uherek, C., & Schüttrumpf, J. (2018). Activity of indatuximab ravtansine against triple-negative breast cancer in preclinical tumor models. Pharmaceutical research, 35(6), 118.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-495CT | Mouse Anti-SDC1 Recombinant Antibody (TAB-495CT) | FC, WB | Mouse IgG1, κ |
TAB-495CT-S(P) | Mouse Anti-SDC1 Recombinant Antibody; scFv Fragment (TAB-495CT-S(P)) | FC, WB | Mouse scFv |
TAB-495CT-F(E) | Mouse Anti-SDC1 Recombinant Antibody; Fab Fragment (TAB-495CT-F(E)) | FC, WB | Mouse Fab |
There are currently no Customer reviews or questions for TAB-197. Click the button above to contact us or submit your feedback about this product.
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-197, RRID: AB_3111866)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.